Key result
Pharmacological treatment for new-onset atrial fibrillation in the ICU was typically initiated at a median heart rate of 128 bpm and was not associated with sustained reversion to sinus rhythm (HR 1.44; 95% CI 0.94-2.20).
Why the study?
To define haemodynamic thresholds for pharmacological treatment of new-onset atrial fibrillation in critically ill patients and examine associations with short-term clinical outcomes.
Does pharmacological treatment improve reversion to sinus rhythm or in-hospital mortality in critically ill adults with new-onset atrial fibrillation?
Cohort (n=210)
Yes
Does pharmacological treatment improve reversion to sinus rhythm or in-hospital mortality in critically ill adults with new-onset atrial fibrillation?
Pharmacological treatment for new-onset atrial fibrillation in the ICU is typically initiated at heart rates around 130 bpm but does not appear to independently improve reversion to sinus rhythm or in-hospital mortality.
Pharmacological treatment for new-onset AF in critically ill patients lacks independent benefit for rhythm control and may prolong ICU stay; leaves open optimal thresholds.
Objective: To define haemodynamic thresholds for pharmacological treatment of new-onset atrial fibrillation (NOAF) in critically ill patients and examine associations with short-term outcomes including reversion to sinus rhythm and in-hospital mortality. Design setting and participants: prospective multicentre observational cohort study conducted across six Australian intensive care units (ICUs) from December 2024 to September 2025. Adult patients (≥18 years) who developed NOAF during ICU admission were included. A Cox proportional hazards model treating time to treatment as a time-dependent covariate was used to assess associations between pharmacological therapy and secondary outcomes. Main outcome measures: The primary outcome was heart rate at initiation of the first pharmacological therapy for NOAF. Secondary outcomes included mean arterial pressure at time of treatment, reversion to sinus rhythm, haemodynamic deterioration, ICU length of stay, and in-hospital mortality. Results: Four hundred eighty-two patients were screened for eligibility and 210 met the inclusion criteria. One hundred fifty-four (73.3%) received pharmacological treatment for NOAF. The median heart rate at treatment initiation was 128 beats per minute (interquartile range [IQR]: 113-147) and median mean arterial pressure 76 mmHg (IQR: 70-87). Pharmacological treatment was not independently associated with sustained reversion to sinus rhythm (adjusted hazard ratio: 1.44, 95% confidence interval [CI]: 0.94-2.20) or in-hospital mortality (adjusted odds ratio: 0.96, 95% CI: 0.36-2.58). Pharmacological treatment was associated with prolonged ICU stay (multiplicative adjusted effect: 1.39, 95% CI: 1.06-1.82). Conclusions: Pharmacological treatment for NOAF is typically initiated at heart rates approximating 130 bpm. After accounting for time-dependent exposure, pharmacological treatment was not independently associated with reversion to sustained sinus rhythm. Given the methodological limitations encountered, these findings warrant validation in randomised trials to better define optimal treatment strategies for NOAF in critical illness.
No takes yet. Share an insight, caveat, or question.
Walker et al. (2026) conducted a cohort in New-onset atrial fibrillation (NOAF) in critically ill patients (n=210). Pharmacological treatment vs. No pharmacological treatment was evaluated on Heart rate at initiation of the first pharmacological therapy for NOAF. Pharmacological treatment for new-onset atrial fibrillation in the ICU was typically initiated at a median heart rate of 128 bpm and was not associated with sustained reversion to sinus rhythm (HR 1.44; 95% CI 0.94-2.20).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: